CD4 and neoplasm: Watson et al [25] found that in tumor-bearing mice, aberrant antigen presentation preferentially expanded CD8+ T cells (but not CD4+ cells), which failed as effectors of cytotoxicity against tumor cells; instead, they acted to down-regulate further immune responses to tumor-associated antigens.